Virios Therapeutics (NASDAQ:VIRI) Stock Price Up 1.7% – Time to Buy?

Virios Therapeutics, Inc. (NASDAQ:VIRI) was up 1.7% during trading on Thursday . The stock traded as high as $3.1799 and last traded at $3.08. Approximately 20,139 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 1,049,645 shares. The stock had previously closed at $3.03.

Virios Therapeutics Trading Up 1.7%

The company has a market cap of $59.31 million, a P/E ratio of -11.41 and a beta of 1.58. The firm’s fifty day moving average price is $4.43 and its 200-day moving average price is $5.09.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.

The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.